BURLINGAME, Calif., Feb. 5 /PRNewswire/ -- BioSeek, Inc. today
announced that Roy A. Whitfield has been elected executive chairman of the
Company's board of directors. Mr. Whitfield had joined BioSeek's board of
directors and served as a business advisor to the Company since November,
2005.
"Roy's management experience and expertise in drug discovery and
business development have been extraordinarily valuable to BioSeek thus
far. We look forward to his continued leadership and guidance as executive
chairman as we advance our internal drug discovery and development efforts
and continue to secure corporate partnerships that capitalize upon our
BioMAP(R) screening systems platform," said Michael C. Venuti, Ph.D., CEO
of BioSeek.
Roy Whitfield has over 20 years of management and governance experience
in the biotechnology industry. Most recently, Roy served as CEO and
Chairman of Incyte Corporation, a genomics company he co-founded in 1991.
Incyte pioneered the commercialization of high throughput and information
technology in pharmaceutical and medical research. At Incyte, Roy executed
the first genomics initial public offering (IPO) and later raised over $700
million in financing. In 1997, he was named Northern California
"Entrepreneur of the Year" for Life Sciences. Roy also serves on the boards
of directors of Incyte Corporation, Nektar Therapeutics, Illumina and
several private companies, and in the past served on the boards of Aurora
Biosciences and the Biotechnology Industry Organization (BIO). Roy received
a B.A. degree from Oxford University and an M.B.A. from Stanford
University.
About BioSeek
BioSeek is improving the success rate of pharmaceutical research and
development by integrating human biology from the early stages of drug
discovery onward. The Company's BioMAP(R) Systems incorporate predictive
human cell-based disease models that generate uniquely informative activity
signatures for each potential drug, driving the selection and development
of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology
in collaborations to enhance the productivity of its pharmaceutical
partners' pipelines, and in the Company's internal programs to identify
promising compounds for proprietary development in the fields of
inflammation, cardiovascular diseases, autoimmune diseases, and related
indications.
For more information, go to http://www.bioseekinc.com
BioSeek Contacts:
BioSeek, Inc.
Michael Venuti, Ph.D.
CEO
Tel: 650.552.0754
MacDougall Biomedical Communications
Jennifer Greenleaf
Tel: 781.235.3060
SOURCE BioSeek, Inc.
 back to top
Related links:
http://www.bioseekinc.com
CONTACT:
Michael Venuti, Ph.D., CEO of BioSeek, Inc.,
+1-650-552-0754; or Jennifer Greenleaf of MacDougall Biomedical
Communications for BioSeek, Inc., +1-781-235-3060
|
